An embolisation agent is a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate having CPS ratios between 1-1000 cps. The invention is particularly related to a medical method and medical device used in treatments which enable to obturate, superficial varicosity, Pake and hemorrhoids with embolisation. By means of the device and method subject to the invention the progression of varicose veins, Pake and internal and external hemorrhoids can be stopped, obturated or clogged.

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.

Storage and mixing systems and methods for pasty multicomponent polymethylmethacrylate bone cements, the systems and methods comprise a first tubular cartridge with a first cylindrical internal space containing a first starting component, a first dispensing plunger, a second tubular cartridge that is arranged within the first tubular cartridge. The external wall of the second cartridge touches against the internal wall of the first cartridge and is attached to the internal wall of the first cartridge, whereby the second cartridge contains a second starting component and has a second dispensing plunger arranged in it, whereby a pressing device with a clamping edge for compressing the second cartridge that can be propelled axially in the internal space of the first cartridge is arranged, as seen from the cartridge head, behind the first dispensing plunger and the second dispensing plunger. The pressing device can be propelled appropriately in the direction of the cartridge head such that the second cartridge is being progressively compressed axially during the motion of the pressing device such that, in the process, the first dispensing plunger and the second dispensing plunger are propelled in the direction of the cartridge head.

Storage and mixing systems and methods for pasty multicomponent polymethylmethacrylate bone cements, the systems and methods comprise a first tubular cartridge with a first cylindrical internal space containing a first starting component, a first dispensing plunger, a second tubular cartridge that is arranged within the first tubular cartridge. The external wall of the second cartridge touches against the internal wall of the first cartridge and is attached to the internal wall of the first cartridge, whereby the second cartridge contains a second starting component and has a second dispensing plunger arranged in it, whereby a pressing device with a clamping edge for compressing the second cartridge that can be propelled axially in the internal space of the first cartridge is arranged, as seen from the cartridge head, behind the first dispensing plunger and the second dispensing plunger. The pressing device can be propelled appropriately in the direction of the cartridge head such that the second cartridge is being progressively compressed axially during the motion of the pressing device such that, in the process, the first dispensing plunger and the second dispensing plunger are propelled in the direction of the cartridge head.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition.

The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition.